Research Analysts’ Weekly Ratings Changes for ACADIA Pharmaceuticals (ACAD)

A number of firms have modified their ratings and price targets on shares of ACADIA Pharmaceuticals (NASDAQ: ACAD) recently:

• 12/8/2025 – ACADIA Pharmaceuticals had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/4/2025 – ACADIA Pharmaceuticals had its “buy” rating reaffirmed by analysts at UBS Group AG. They now have a $35.00 price target on the stock.
• 12/2/2025 – ACADIA Pharmaceuticals had its price target raised by analysts at Mizuho from $24.00 to $29.00. They now have a “neutral” rating on the stock.
• 12/1/2025 – ACADIA Pharmaceuticals had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – ACADIA Pharmaceuticals had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/17/2025 – ACADIA Pharmaceuticals had its price target lowered by analysts at JPMorgan Chase & Co. from $33.00 to $31.00. They now have an “overweight” rating on the stock.
• 11/8/2025 – ACADIA Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 11/6/2025 – ACADIA Pharmaceuticals had its price target lowered by analysts at Royal Bank Of Canada from $34.00 to $32.00. They now have an “outperform” rating on the stock.
• 11/6/2025 – ACADIA Pharmaceuticals had its price target raised by analysts at Needham & Company LLC from $28.00 to $29.00. They now have a “buy” rating on the stock.
• 10/21/2025 – ACADIA Pharmaceuticals is now covered by analysts at Citigroup Inc.. They set a “buy” rating and a $33.00 price target on the stock.
• 10/14/2025 – ACADIA Pharmaceuticals had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.

Insiders Place Their Bets

In related news, EVP Mark C. Schneyer sold 10,262 shares of ACADIA Pharmaceuticals stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $23.69, for a total transaction of $243,106.78. Following the completion of the sale, the executive vice president owned 53,338 shares of the company’s stock, valued at approximately $1,263,577.22. This trade represents a 16.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider James Kihara sold 4,084 shares of the business’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $23.69, for a total value of $96,749.96. Following the completion of the transaction, the insider owned 25,058 shares in the company, valued at $593,624.02. This trade represents a 14.01% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 47,844 shares of company stock worth $1,093,684 in the last quarter. 28.30% of the stock is currently owned by corporate insiders.

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.